DURAGESIC-12
LOE ApproachingNDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Aug 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DURAGESIC-12 is a transdermal extended-release film formulation approved in 1990 by Johnson & Johnson. The product treats chronic pain conditions through sustained transdermal delivery. The mechanism of action and specific indications are not disclosed in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting smaller marketing teams focused on lifecycle extension and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DURAGESIC-12 currently shows zero linked open positions, reflecting its LOE-approaching status. Career opportunities on this product focus on managed decline, payer negotiations, and operational efficiency rather than growth or innovation roles.
Brand Manager (Legacy)Field Sales
Worked on DURAGESIC-12 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.